Cancer Pain
Cancer pain is a multifaceted clinical syndrome defined as pain resulting directly or indirectly from neoplastic disease or its treatment. Its pathogenesis is complex, involving both nociceptive and neuropathic mechanisms. Tumor infiltration of bone, nerves, or viscera can cause tissue destruction, inflammation, and compression, leading to the activation of nociceptors and subsequent pain signaling. Additionally, cancer therapies such as chemotherapy, radiotherapy, and surgical interventions may induce pain through nerve injury or inflammatory processes. The health impacts of cancer pain are profound, encompassing not only physical suffering but also psychological distress, impaired function, decreased quality of life, and increased morbidity. Uncontrolled pain may hinder optimal oncologic management, contribute to depression and anxiety, and result in significant social and economic burdens.
Somatic pain in cancer arises from the involvement of bones, joints, muscles, or connective tissue by tumor growth or metastasis. It is typically well localized and described as aching, throbbing, or stabbing. Bone metastases are a common source, leading to persistent, often severe discomfort that may be exacerbated by movement or weight-bearing.
Visceral pain is generated by the infiltration, compression, or stretching of internal organs such as the liver, pancreas, or intestines by malignant lesions. This pain is often poorly localized, deep, and may be described as cramping or pressure-like. It can be accompanied by autonomic symptoms such as nausea or sweating and may refer to distant sites due to shared neural pathways.
Neuropathic pain results from direct injury or dysfunction of the peripheral or central nervous system by tumor invasion, treatment-related nerve damage, or paraneoplastic phenomena. It is often characterized by burning, shooting, or electric shock-like sensations, and may be associated with allodynia or hyperalgesia. Neuropathic pain is frequently challenging to manage and can be persistent even after tumor control.
Incident or breakthrough pain refers to transient exacerbations of pain that occur spontaneously or in relation to specific activities, superimposed on otherwise controlled baseline pain. It is usually intense, rapid in onset, and of short duration, often requiring specific management strategies distinct from background pain control.
Cancer pain is a prevalent and significant clinical concern, affecting approximately 30-50% of patients at diagnosis and up to 70-90% of those with advanced or metastatic disease. Epidemiological studies indicate that around two-thirds of cancer patients will experience pain during their illness, and one-third will suffer from moderate to severe pain. The prevalence and severity of pain vary by cancer type, stage, and treatment modality, with higher rates observed in cancers involving the bone, pancreas, head and neck, or nervous system. Despite advances in oncologic care, a substantial proportion of patients continue to report inadequate pain relief, underscoring the need for effective assessment and management. Cancer pain contributes to significant morbidity, including impaired physical function, psychological distress, and reduced quality of life, and remains a leading cause of hospital admissions and palliative care referrals.
The diagnosis of cancer pain requires a comprehensive clinical assessment, integrating patient history, physical examination, and relevant diagnostic investigations. Clinicians should obtain a detailed pain history, including onset, duration, intensity, quality, location, temporal pattern, aggravating and relieving factors, and impact on function and mood. Standardized pain assessment tools, such as the Numeric Rating Scale (NRS), Visual Analog Scale (VAS), or Brief Pain Inventory (BPI), are employed to quantify pain severity and monitor response to treatment. Physical examination focuses on identifying signs of tumor progression, neurological deficits, or treatment-related complications. Diagnostic imaging, including X-rays, CT scans, MRI, or bone scans, may be indicated to localize the source of pain, evaluate for bone metastases, or assess for nerve involvement. Laboratory tests may be utilized to rule out infection, metabolic disturbances, or paraneoplastic syndromes. The differentiation between nociceptive and neuropathic pain components is critical for guiding therapy. Multidisciplinary evaluation, involving oncology, pain management, and palliative care specialists, is often necessary for complex cases. Diagnostic criteria emphasize the temporal relationship between pain and cancer diagnosis, anatomical correlation with tumor sites or treatment fields, and exclusion of alternative etiologies.
Tapentadol hydrochloride is utilized for the management of moderate to severe cancer pain, offering dual mechanisms of action as a mu-opioid receptor agonist and norepinephrine reuptake inhibitor. Cannabis sativa L. extract, specifically nabiximols, is employed as an adjunctive therapy for cancer pain, particularly in patients with refractory symptoms, harnessing the analgesic properties of cannabinoids. Morphine hydrochloride is a cornerstone opioid analgesic in cancer pain control, indicated for moderate to severe pain and available in various formulations to suit individual patient needs. Fentanyl, including its SDI and citrate formulations, is indicated for severe cancer pain, particularly breakthrough pain, and is administered via multiple routes such as transdermal patches and transmucosal preparations. Tramadol hydrochloride serves as a centrally acting analgesic for mild to moderate cancer pain, often used when non-opioid therapies are insufficient. Diclofenac sodium, a nonsteroidal anti-inflammatory drug, is prescribed for the relief of mild to moderate cancer-related pain, especially when inflammation is a contributing factor. Methadone and its hydrochloride form are indicated for severe cancer pain, particularly in cases with a neuropathic component or when rotation from other opioids is required due to tolerance or adverse effects. Oxycodone hydrochloride is another potent opioid used for managing moderate to severe cancer pain, available in immediate and controlled-release formulations to provide continuous analgesia. Morphine sulfate is widely used in the treatment of moderate to severe cancer pain, offering flexible dosing and routes of administration to accommodate varying patient requirements.
| Structure | Generic Name | CAS Registry Number | Molecular Formula | Molecular Weight |
|---|---|---|---|---|
 | tapentadol hydrochloride (Rec INNM; USAN) | 175591-09-0; 175591-23-8 (free base) | C14 H23 N O . Cl H | 257.799 |
| Cannabis sativa L. extract; nabiximols (USAN) | 56575-23-6 | |||
 | morphine hydrochloride; thebametten | 52-26-6 | C17 H19 N O3 . Cl H | 321.799 |
 | fentanyl (Rec INN; USAN; BAN; JAN); fentanyl SDI | 437-38-7 | C22 H28 N2 O | 336.471 |
 | tramadol hydrochloride (Rec INNM; USAN; BANM) | 36282-47-0 | C16 H25 N O2 . Cl H | 299.836 |
 | diclofenac sodium (Rec INNM; USAN; BANM; JAN) | 15307-79-6; 15307-86-5 (free acid) | C14 H10 Cl2 N O2 . Na | 318.13 |
 | fentanyl citrate (Rec INNM; USAN; BANM; JAN) | 437-38-7 (free base); 990-73-8 | C22 H28 N2 O . C6 H8 O7 | 528.594 |
 | methadone; methadone hydrochloride (Rec INNM; USAN; BANM) | 1095-90-5; 76-99-3 (free base) | C21 H27 N O . Cl H | 345.906 |
 | oxycodone hydrochloride (Rec INNM; USAN; BANM; JAN) | 124-90-3; 76-42-6 (free base) | C18 H21 N O4 . Cl H | 351.825 |
 | morphine sulfate (USAN; BANM; JAN); morphine sulphate | 2 C17 H19 N O3 . 5 H2 O . H2 O4 S | 758.83 |
Make Order
Experimental Scheme
Implementation
Conclusion
